23:51 , Jan 6, 2017 |  BC Extra  |  Financial News

Cavion raises $26.1M series A

Cavion Inc. (Charlottesville, Va.) raised $26.1 million in a series A round co-led by Lilly Ventures and Novartis Venture Fund. Enso Ventures also participated, as did undisclosed existing investors. The company is developing T-type calcium...
07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphodiesterase 3B, cGMP-inhibited (PDE3B); caveolin 3 (CAV3)

Cardiovascular disease INDICATION: Myocardial infarction (MI) In vitro and mouse studies suggest inhibiting PDE3B could help treat MI. In a mouse model of cardiac ischemia/reperfusion injury, cardiac-specific knockout of PDE3B decreased infarct size, increased levels...